A B S T R A C T Individuals with cancer have previously been shown to have abnormal chemotactic responsiveness. Surgical removal of the tumor often resulted in normalization of monocyte function, which suggests that human neoplasms might inhibit monocyte chemotaxis by release of soluble mediators. We therefore examined the effects of cancerous effusions on monocyte polarization, i.e., the rapid change in monocyte morphology from round to a triangular "motile" configuration in response to chemoattractants. All 17 malignant effusions, representing 15 tumor types, inhibited monocyte polarization induced by the chemoattractant N -formyl -methionyl -leucylphenylalanine by 45-89% (mean 55.9+12.7%, P < 0.01) in blinded assays. None of 17 benign effusions significantly inhibited polarization (0-15%, mean 6 .2+±4.2%). Dilutions of cancerous effusions as low as 1:200 produced inhibition that was time, temperature, and dose dependent. Monocyte polarization induced by activated serum or by chemotactic lymphokine was also blocked by cancerous effusions. The inhibitory activity affected the monocyte directly, and did not destroy the chemoattractant or block the polarization of granulocytes to chemotactic factors. High pressure liquid chromatography of five cancerous fluids revealed three peaks of inhibitory activity: -200,000, 46,000-+13,000, and 21,000+3,000 daltons. Fractionation of noncancerous effusions revealed only small amounts of the highest molecular weight inhibitory INTRODUCTION Macrophages, working alone or in concert with lymphocytes, can destroy cancer cells in vivo and in vitro (1, 2) . Few macrophages, however, are generally found within progressively growing tumors, and their numbers are often inversely related to the tumor's metastatic potential (3) (4) (5) . Moreover, cancer patients frequently have abnormally functioning monocytes, which can regain normal function after cancer therapy or tumor removal (6) (7) (8) (9) (10) . Thus, it has been hypothesized that cancer cells may produce factors that alter monocyte-macrophage functions, thereby subverting immune surveillance (11) . Indeed, in rodents, neoplasms produce agents which inhibit macrophage chemotaxis in vitro and macrophage accumulation in vivo (12) (13) (14) (15) .
A major barrier to determining the effects of neoplasms on mononuclear phagocyte function in humans has been the lack ofa suitable assay. Previous monocyte function studies, including chemotaxis (6-10), adherence (16) , tumor cytotoxicity (5) , and superoxide production (17) , have demonstrated variable macrophage abnormalities in cancer patients, but the assays employed have been relatively cumbersome, with no sharp differentiation between cancerous and noncancerous conditions.
In this study, we utilized a new assay, quantification of monocyte polarization to chemoattractants (18) (Table I) were quite similar when compared by age, sex, and nutritional status. The average serum total protein and albumin levels for the two groups were, for cancer patients, total protein, 6 .0+1.0 gldl and albumin, 3.0+0.7 g/dl; and, for noncancer patients, total protein, 6 .7+0.4 g/dl and albumin 2.9+0.8 g/dl. Most patients (90%) were receiving some medications, but there were no consistent differences in those received by the two groups. The most commonly used medications were narcotics, hypnotics, vitamins, thiazides, and aminophylline. The only patients with culture-proven infection were two with empyema and one with peritonitis. (20) . The percentages of peroxidase-positive cells and monocytes as determined morphologically with a WrightGiemsa stain were similar, -30±10%, depending on the donor. Granulocytes were isolated from the cell pellet of the Ficoll-Hypaque density gradient as previously described (19) . Chemotactic peptides and other reagents. N-formylmethionyl-leucyl-phenylalanine (FMLP) was obtained from Sigma Chemical Co., St. Louis, Mo. Zymosan-activated human serum and lymphocyte-derived chemotactic factor were prepared as previously described (21) .
Polarization assay. The percentage of monocytes or granulocytes that polarized in the presence of a given stimulus was measured by incubating the cells (106/ml monocytes or polymorphonuclear leukocytes [PMN] in GBSS) at 37°C with the stimulus in a polypropylene tube (12 x (18, 22) . Cell suspensions were kept at 40C until examined by phase-contrast microscopy. All assays were performed in duplicate and 200 cells from each tube were examined under x400 magnification with a hemocytometer. The percentage of total cells assuming a bipolar configuration was determined.
Because the monocyte suspensions also contained lymphocytes, the percentage of polarized monocytes was determined by the formula: % monocytes polarized = (% total cells polarized/% peroxidase positive cells) x 100. Lymphocytes do not polarize in this assay (18) .
Because the granulocyte suspensions were >98% granulocytes, the percentage of total cells polarized was used as the actual percentage of granulocytes polarized.
Inhibition of polarization. The ability of effusions to inhibit polarization to a chemotactic stimulus was tested by preincubating the fluids at a final concentration of 10.0, 2.0, or 0.2 absorbance 280 nm U/ml GBSS with monocytes (106/ml) or granulocytes (106/ml) for 10 min at 37°C. The chemotactic stimulant, at a concentration that induced maximum polarization, was then added to the cells for an additional 7.5 min at 37°C. Ice-cold buffered formaldehyde was then added to stop the reactions. All effusions (cancerous and noncancerous) were tested blindly and in duplicate.
Inhibition of chemotaxin-induced polarization was then calculated, after subtraction of background polarization (polarization in presence of GBSS alone), as: % inhibition = (chemotaxin polarization with buffer -chemotaxin polarization with effusion/chemotaxin polarization with buffer)
x 100.
Inhibition of chemotaxis. To test fluids for ability to inhibit chemotaxis induced by FMLP, a modification of the leading front chemotaxis assay was used (23) . Monocytes (1.5 x 106/ml) were preincubated with the indicated effusion at room temperature for 10 min. This mixture was then added to the top compartment of a blind-well chemotaxis chamber (21) . The lower coinpartment contained the effusion with 'Abbreviations used in this paper: CFI, chemotactic factor inactivators; FMLP, N-formyl-methionyl-leucyl-phenylalanine; GBSS (24) .
Effusion fractionation by high-pressure liquid chromatography (HPLC) or ultrafiltration. Cancerous and noncancerous effusions were fractionated by HPLC. Two silicabased HPLC columns were coupled in series (Micropak TSK 3000 SW, 7.5 mm x 50 cm, followed by Micropak TSK 2000 SW, 7.5 mm x 50 cm, Varian Associates, Inc., Instrument Group, Palo Alto, Calif.). Liquid phase for all chromatographic runs was 0.15 M NaCl with a flow rate of 1.5 ml/min. A 100-,ul sample was fractionated, and eluted proteins were monitored by absorbance at 254 nm. Individual column fractions, kept on ice, wvere then assayed for stimulation or inhibition of polarization. Approximate molecular weights corresponding to the inhibitory and stimulatory fractions were determined by the method of Andrews (25) .
Ultrafiltration using Amicon CF25 centriflo membrane cones (25,000 mol wt cutoff, Amicon Corp., Scientific Sys. Div., Lexington, NMass.) was also used to fractionate effusions. Effusions were standardized to 40 absorption 280 nm U/ml by dilution with phosphate-buffered saline (p1I 7.0). Small portions (3-6 cm3) vere filtered through the Amicon membranes by centrifugation at 4°C and 400 g for 60 min. Repeat absorbance 280 measurements were done on the low-molecular weight fractions. Dilutions of 1/5, 1/100, and 1/200 were made from the low-molecular veight fractions, and these were tested for stimulation or inhibition of polarization.
Sepharose-coupled trypsin and trypsin inhibitor. Bovine pancreas trypsin and soybean trypsin inhibitor (Sigma Chemical Co.) were 1)oth coupled to cyanogen-bromide activated Sepharose 4B (Pharinacia Fine Chemicals). Material to be tested wvas incubated for either 30 or 60 min with the coupled Sepharose at a ratio of 0.1 ml Sepharose to 0.9 ml material. The Sepharose was removed by centrifugation.
Antibodies and other reagents. Monoclonal antibodies to murine leukemia virus P,5(E) (both IgG2a and IgG2b), murine leukemia virus GP70 (IgG2a and IgG2b), and human Ia were all purchased from New England Nuclear, Boston, Mass. Three different antibodies to P,5(E) are designated as aP15(E)a, aPi5(E)b, and aPis(E)c; and tvo different antibodies to GP70 are designated aGP7ob anid aGP70e. The isolation, characterization, and specificity of these antibodies have been previously described (26 Protein determinations. Protein concentrations of ultrafiltrates were determined by the method of Lowry et al. (28) .
Statistical significance. Statistical analyses were done on each daily experiment, comparing individual benign and malignant samples with FMLP controls (analysis of variance and Q-test). These data were used to compare the cumulative group of malignant fluids with the cumulative group of benign fluids (chi-square).
RESULTS
Ability of effusions to induce monocyte polarization. To determine whether effusions contained inhibitors of monocyte polarization to chemoattractants, it was first necessary to test them for their inherent ability to induce polarization. Noninfected benign and malignant fluids exhibited little intrinsic polarizing activity (Table II) . These effusions also did not cause To determine whether the inhibitors present in cancerous effusion could reverse polarization, normcal moniocytes were first stimulated with FMLP for 10 min, thenl cancierouis effuisionI was added and the cells incubated for varying lengths of time before being fixed. The results of two experiments (data not shown) indicated that addition of cancerous effusion to polarized monocytes reversed that polarization to the same levels obtained by preincubation of the cells with effusion, and that this reversal was complete within 15 min after the effusion was added.
Fluids from patients with a wide variety of solid tumnors contained inhibitory activity. Even chylous ascites (mixed histiocytic-lyymphocytic lymphoma) and leukemic (acute myelomonocytic) pericardial effusion contained inhibitory activity. Cerebrospinal fluid from a patient with carcinomatous meningitis due to metastatic colon cancer and malignant breast cyst fluid were also inhibitory. As anticipated, unfractionated malignant ovarian ascites fluid did not appear to depress the response to FMLP, because the ascites itself induced polarization, particularly at high concentrations (Table  III) . At lower concentrations, however, the polarizing activity of one of the two ovarian ascites was diluted out and inhibitory activity became evident.
Inhibition of mtonocyte chemotaxis by malignant effusions. Several effusions were assayed for their ability to inhibit monocyte chemotaxis. The mean inhibitory activity, at each dose tested, was greater in cancerous fluids (Fig. 2) . Even at the highest dose tested, however, only 11 of 17 malignant fluids were inhibitory (59.7+25.7%, P < 0.05). Three of nine be- (Fig. 3) . A high-molecular-weight inhibitory peak was also found. The major inhibitory activity, however, was found in two peaks: one eluting just before ribonuclease, the other with ovalbumin. The approximate molecular weights of these peaks, determined by the technique of Andrews (25) , were 20,000 and 45,000.
Column fractionation ofmalignant melanoma pleural fluid confirmed three broad but distinct inhibitory peaks (Fig. 4A) . The unfractionated fluid did not polarize, and stimulatory fractions were not found (data not shown). Column fractionation ofbenign pulmonary infarction pleural fluid uncovered only the highest molecular weight inhibitory peak (Fig. 4B) . No polarizing peaks were found. The unfractionated benign effusion neither inhibited nor stimulated polarization.
HPLC has revealed the highest molecular weight peak as well as the two low molecular weight inhibitory peaks in all five malignant effusions tested (melanoma pleural, liposarcoma pleural, lung adenocarcinoma pleural, prostate adenocarcinoma pleural, and ovarian peritoneal). Only the highest molecular weight peak (.200,000) was found in fractions from four benign effusions (uremic pleural, pulmonary infarction pleural, heart failure pleural, and cirrhosis peritoneal) and in four sera from patients without cancer (results not shown). The approximate mean molecular weights of the three inhibitory peaks in the malignant effusions were >200,000; 46,000±+13,000 (range 36,000-52,000); and 21,000±3,000 (range 18,000-25,000).
Since the polarizing activity of ovarian ascites was of high molecular weight, and most of the inhibitory activity of low molecular weight, Amicon cone ultrafiltration (mol wt < 25,000) was used to separate these activities. In two of two ovarian samples, ultrafiltration resulted in significant inhibitory activity and no polarizing activity in the ultrafiltrate (Table III) . One infected benign effusion (bacterial peritonitis) was also ultrafiltered to see whether any low molecular weight inhibitors could be separated (Table III) . The low molecular weight portion did not contain inhibitory activity.
Site of action of inhibitors of polarization. To determine whether the inhibitory activity of cancer fluids was directed at the chemoattractant or at the cell, experiments using preincubation techniques were designed. Malignant fluids were preincubated at 37°C for 10 min with either FMLP alone or the monocytes alone. After this, either FMLP or monocytes were added to the incubation mixtures for an additional 7.5 min at 37°C. The cells were then fixed, and polarization was measured. The results suggested that the inhibitory factor(s) affected the monocytes rather than FMLP (Table IV) , because preincubation of fluids with cells resulted in inhibition, whereas preincubation of fluids with FMLP did not.
To test further whether the inhibitors were celldirected, monocytes (in 5 ml) were preincubated with fluid ultrafiltrates and then washed four times with 50 ml of buffer. Upon stimulation with FMLP, monocyte polarization was still strongly inhibited in cells that had been exposed to cancerous ultrafiltrate and then washed (Table V) . Inhibition ofpolarization induced by several chemoattractants. To see whether malignant fluids inhibit polarization to chemoattractants other than FMLP, zymosan-activated human serum, or lymphocytederived chemotactic factor was used as the chemotactic factor. Polarization induced by all three agents was inhibited by malignant but not by benign effusions (Table VI) .
Effects ofeffusions on the polarization ofPMN. To test the specificity of the inhibitory activity for monocytes, malignant effusions were also incubated with PMN, and FMLP-induced polarization was measured. No inhibition of PMN polarization occurred, despite varying malignant fluid concentration, FMLP concentrations, and incubation times (Table VII) .
Temperature and protease sensitivity. Ultrafiltered effusion from a patient with cancer was incubated for varying times at 370, 560, or 70°C and then tested for its effects on monocyte polarization. An ultrafiltrate that had been kept on ice was used as control. Incubation for 1 h at 37°C resulted in no loss of activity while 2 h resulted in a 30% decrease in activity. Activity was stable after 30 min at 56°C but was only half as potent after 60 min. Incubation at 70°C for even 10 min resulted in the loss of inhibitory activity. Ultrafiltered malignant effusion was tested for protease sensitivity by incubation with trypsin coupled to Sepharose. Incubation for 30 or 60 min at 220C caused a decrease in the inhibition of polarization from 60% to 9 and 10%, respectively. Incubation with trypsin inhibitor coupled to Sepharose had no effect on the inhibitory activity.
Removal of inhibitory activity by monoclonal antibody. The ultrafiltered effusions (containing 150-250 ,ug protein/ml) from eight different cancer patients were individually incubated with monoclonal antibody reactive to murine leukemia virus P,5(E), or with other antibody preparations, adjusted to contain the same amount of protein as the anti-P,5(E). The antibodies were then removed by adsorption to formalin-fixed S. aureus, and the materials tested for effects on monocyte polarization (Table VIII) filtrates absorbed with monoclonal antibody to P15(E). Anti-P15(E) antibodies of either the IgG2a or IgG2b subclasses were capable of absorbing the inhibitory activity even though they are reported to react with different determinants on the P,5(E) molecule (26 cytes (Table VIII) . The extract significantly inhibited monocyte polarization and the inhibitory activity was absorbed by monoclonal anti-P,5(E) antibodies of both the IgG2a and IgG2b subclasses. Murine IgG2a and monoclonal anti-GP70 had no effect on this inhibitory activity. * Variouis cancerous or noncanicerous effusions were preincubated with monocytes (106/ml) for 10 min at 37°C, the cells were then challenged with the indicated chemoattractant for an additional 7.5 min at 37°C, fixed, and examined by phase-contrast microscopy (x400).
t Percent inhibitioni of polarization to the indicated chemoattractant (Ctx) was calculated, after subtractioni of background polarization (to buffer alone), as: % inhibition = (Ctx polarization with buffer -Ctx polarization with effusion/Ctx polarization with buffer) x 100.
Four malignant effusions that had not been ultrafiltered were also tested before and after absorption with anti-P,5(E) ( Table IX) . The monoclonal anti-P15(E) removed a significant portion of the activity from these fluids. Murine IgG2a or monoclonal anti-GP70 had no significant effect on inhibition. To see whether the inhibitors which affected polarization and chemotaxis were antigenically related, five effusions which inhibited chemotaxis were preincubated with buffer alone or with buffer containing either monoclonal anti-P,5(E) or monoclonal anti-GP70. Antibody was removed by S. aureu.s absorption and the fluids were tested for their ability to inhibit chemotaxis. The average inhibition of the five effusions after preincubation with buffer or anti-GP70 was 72 and 77%, respectively, whereas the fluids absorbed with anti-P15(E) inhibited chemotaxis by aIn average of onlly 33% (data not shown).
In the abseniee of FMLP, effusions or ultrafiltrates treated with anti-P15(E) plus S. aureus had no polarizing or chemotactic activity. Thus, the ability of anti-P15(E) to block the inhibitory activity in malignant effusions was not due to the generation of polarizing or chemotactic activity.
DISCUSSION
Although the concept of immune surveillance, as a mechanism ofhost resistance to cancer, offers hope that highly specific, more effective, and less toxic therapies for tumors can be developed, extensive clinical immunotherapy trials (29, 30) have not yet fulfilled expectations. In fact, the role of the immune system in cancer control has been seriously questioned. Many arguments against immune surveillance, however, underplay the role of the macrophage. Evidence supporting the importance of the macrophage in resisting the development and spread of cancer has recently received increasing attention (11) .
Since abnormalities of monocyte activities, particularly chemotaxis, have been reported in humans and animals with cancer (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , the present study sought to determine whether inhibitors of monocyte function were present in human cancerous effusions. A new assay, monocyte polarization in response to chemoattractants, proved to be rapid and reproducible in blind experiments. More importantly, the polarization assay appears to be sensitive and specific in detecting monocyte inhibitors in the effusions of cancer In characterizing the inhibitory activity by means of high pressure gel filtration, three fractions of -2200,000, 46,000+13,000 and 21,000+3,000 daltons were found.
Only the highest molecular weight component was present in noncancerous effusions or in normal human serum.
The inhibitory activity found in human cancerous effusions was biologically potent, being active at dilutions of up to 1:200, and appeared to at least partially reside in a protein moiety, because the activity of low molecular weight ultrafiltrates was destroyed by trypsin. This is contrary to the lipid-like inhibitory factor isolated from cell cultures of human breast cancer or melanoma (31) . The inhibitory factors for monocyte polarization are cell-directed and monocyte-specific, in that granulocyte polarization was unaffected. This is similar to the inhibitors of macrophage chemotaxis produced by murine neoplasms (12) . The human inhibitors, moreover, blocked monocyte polarization to all three classes of chemoattractants tested.
Inhibitors of monocyte and granulocyte function had been previously described in normal serum (32, 33) . Most of the previously described inhibitors have been chemotactic factor inactivators (CFI) although celldirected inhibitors were also reported. Increased levels of CFI or cell-directed inhibitors have been found, however, in sera from patients with noncancerous diseases such as cirrhosis, sarcoidosis, leprosy, systemic lupus erythematosus, and chronic periodontitis. Occasional malignant states, especially Hodgkin's disease, have been associated with increased serum levels of CFI or cell-directed inhibitors. Kjeldsberg and Pay (34) described CFI in sera in 19 of 21 patients with cancer of the lung or prostate. No CFI was found in 12 controls. Monocyte chemotaxis was also abnormal in 10 of the cancer patients. In four patients treated and followed, two treated surgically lost CFI, two treated chemotherapeutically did not lose CFI. These CFI and cell-directed inhibitors were described as larger proteins (4, 7, and 10S sedimentation coefficients) than those inhibitors described in this paper.
In previous studies we found that potent inhibition of macrophage accumulation in mice was caused by the injection of a murine leukemia virus envelope protein of 15,000 daltons, termed P15(E) (35) . The inhibitory activities for macrophage accumulation derived from either murine tumors or disrupted murine leukemia viruses were physiochemically and antigenically similar. Antibody raised against disrupted Friend leukemia virus absorbed the inhibitory activity for macrophage accumulation isolated from a murine tumor cell extract (36) . Recent studies by other laboratories have also demonstrated the immunosuppressive potential of type C virus structural proteins. Mathes et al. (37, 38) showed that a 15,000 mol wt protein of feline leukemia virus could abrogate lymphocyte blastogenesis and capping in vitro and reduce the level of antibody formation in vivo. Inhibition of in vitro lymhocyte transformation by disrupted murine leukemia virus has been demonstrated by Fowler et al. (39) .
In the present study we have demonstrated that the low molecular weight inhibitors of monocyte polarization in human effusions are similar to the murine inhibitor of macrophage chemotaxis derived from neoplasms (12) . More importantly, a monoclonal antibody reactive against the P,5(E) component of murine leukemia viruses bound the inhibitory activity derived from all human cancerous effusions tested. These data suggest that the human inhibitory factor may have antigens in common with a structural component ofa murine RNA tumor virus. In addition, extracts of a murine leukemia virus also inhibited human monocyte polarization and this activity was also absorbed by antibody to P,5(E). We can not yet estimate, however, the total extent of the antigenic or structural relationship be- t 0.5 ml of the ultrafiltrate was incubated for 15 min at 22°C with 10 Al of GBSS or GBSS containing 7.5 Ag of the appropriate antibody. 25 M1 of formalin-fixed S. aureus (IgGsorb) was added, the mixture incubated an additional 12 min at 22'C, and the IgGsorb removed by centrifugation at 12,000 g for 2 min.
5 0.1 ml of absorbed ultrafiltrate was incubated for 10 min at 37°C with 0.3 ml of cell suspension containing 4.8 x 105 peroxidase-positive mononuclear cells.
0.1 ml of GBSS or 50 nM FMLP in GBSS was then added to each of duplicate tubes, the tubes incubated an additional 7.5 min at 37C, the cells fixed, and the percentage of polarized monocytes determined. The percentage of inhibition of polarization to FMLP was calculated, after subtraction of background polarization (to buffer alone), as in Fig. 1 .
' These ultrafiltrates were each absorbed with 2.5 jsg of the appropriate antibody.
I Not determined. Thus, the evidence presented here demonstrates that potent inhibitory agents that alter monocyte responsiveiness to chemoattractants are present in human cancerous effusions. We have not yet determined whether these inhibitors are present systemically or are localized to focal tumor microenvironments, although studies to answer this (luestion are ongoing. Similarly, a possible correlation between the amiount of inhibitory activity with the extent of cancer metastasis or tumor burden is being iinvestigated. In any case, assaying for inhibition of monocyte polarization to chemotactic factors provides an apparently useful assay for dif-ferentiating cancerous from noncancerous effusions. This assay could therefore have considerable diagnostic importance. These studies, moreover, support the concept that clinically apparent neoplasms may produce potent inhibitors of monocyte function and thereby sul)vert their destruction by immunological processes requiring macrophage accumulation. If this is the case, immunotherapy specifically designed to counter the inhibition of monocyte response to chemoattractants may be more effective than those regimens currenitly being used.
